Antibodies against the calcium channel β-subunit in Lambert-Eaton myasthenic syndrome

Neurology

Volumn 50, Issue 2, 1998, Pages 475-479

  Verschuuren, J J ^a   Dalmau, J ^b   Tunkel, R ^c   Lang, B ^b   Graus, F ^d   Schramm, L ^b   Posner, J B ^c   Newsom Davis, J ^a   Rosenfeld, M R ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CALCIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EATON LAMBERT SYNDROME; FEMALE; HUMAN; IMMUNIZATION; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0031934763     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.2.475     Document Type: Article

References (28)

1. Anderson H J, Churchill-Davidson HC, Richardson AT. Bronchial neoplasm with myasthenia: prolonged apnoea after administration of succinylcholine. Lancet 1953;2:1291-1293.
2. Eaton LM, Lambert EH. Electromyography and electric stimulation of nerves in diseases of motor unit. Observations on myasthenic syndrome associated with malignant tumors. JAMA 1957;163:1117-1124.
3. O'Neill JH, Murray NMF, Newsom-Davis J. The Lambert-Eaton myasthenic syndrome. A review of 50 cases. Brain 1988;lll:577-596.
4. Motomura M, Johnston I, Lang B, Vincent A, Newsom-Davis J. An improved diagnostic assay for Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 1995;58: 85-87.
5. Lennon VA, Kryzer TJ, Griesman GE, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med 1995;332:1467-1474.
6. Zhang J-F, Randal AD, Ellinor FT, et al. Distinctive pharmacology and kinetics of cloned neuronal Ca2+ channels and their possible counterparts in mammalian CNS neurons. Neuropharmacol 1993;32:1075-1088.
7. 2+ channels in mammalian central neurons. Trends Neurosci 1995;18:89-98.
8. Lang B, Newsom-Davis J, Wray D, Vincent A. Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome. Lancet 1981;2:224-226.
9. Fukunaga H, Engel AG, Osame M, Lambert EH. Paucity and disorganization of presynaptic membrane active zones in the Lambert-Eaton myasthenic syndrome. Muscle Nerve 1982;5: 686-697.
10. Fukunaga H, Engel AG, Lang B, Newsom-Davis J, Vincent A. Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones. Proc Natl Acad Sei USA 1983;80:7636-7640.
11. Peers C, Lang B, Newsom-Davis J, Wray DW. Selective action of myasthenic syndrome antibodies on calcium channel in a rodent neuroblastoma X glioma cell line. J Physiol 1990;421: 293-308.
12. El Far O, Marqueze B, Leveque C, et al. Antigens associated with N- and L-type calcium channels in Lambert-Eaton myasthenic syndrome. J Neurochem 1995;64:1696-1702.
13. Sher E, Gotti C, Canal N, et al. Specificity of calcium channel autoantibodies in Lambert-Eaton myasthenic syndrome. Lancet 1989;2:640-643.
14. Leys K, Lang B, Johnston I, Newsom-Davis J. Calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Ann Neurol 1991;29:307-314.
15. Motomura M, Lang B, Johnston I, Palace J , Vincent A, Newsom-Davis J. Incidence of serum anti-P/Q-type and antiN-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci 1997;147:35-42.
16. Uchitel OD, Protti DA, Sanchez V, Cherskey BD, Sugimori M, Llinas R. P-type voltage- dependent calcium-channel mediates presynaptic calcium influx and transmitter release in mammalian synapses. Proc Natl Acad Sci USA 1992;89:3330-3333.
17. Leveque C, Hoshino T, David P, et al. The synaptic vesicle protein synaptotagmin associates with calcium channels and is a putative Lambert-Eaton myasthenic syndrome antigen. Proc Natl Acad Sci USA 1992;89:3625-3629.
18. Rosenfeld MR, Wong E, Dalmau J, et al. Cloning and characterization of a Lambert-Eaton myasthenic syndrome antigen. Ann Neurol 1993;33:113-120.
19. 2+ channel β-subunits. Biochem Soc Trans 1994;22:483-488.
20. Clouston PD, Saper CB, Arbizu T, et al. Paraneoplastic cerebellar degeneration. III. Cerebellar degeneration, cancer, and the Lambert-Eaton myasthenic syndrome. Neurol 1992;42: 1944-1950.
21. Goldstein JM, Waxman SG, Vollmer TL, Lang B, Johnston I, Newsom-Davis J. Subacute cerebellar degeneration and Lambert-Eaton myasthenic syndrome associated with antibodies to voltage-gated calcium channels: differential effect of immunosuppressive therapy on central and peripheral defects. J Neurol Neurosurg Psychiatry 1994;57:1138-1139.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
23. Towbin H, Staehelin T, Gordon J. A procedure for the electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets. Proc Natl Acad Sci USA 1979;76:4350-4352.
24. Takamori M, Iwasa K, Komai K. Antibodies to synthetic peptides of the alA subunit of the voltage-gated calcium channel in Lambert-Eaton myasthenic syndrome. Neurology 1997;48: 1261-1265.
25. Codignola A, Tarroni P, Clementi F, et al. Calcium channel subtypes controlling serotonin release from human small cell lung carcinoma cell lines. J Biol Chem 1993;268:26240-26247.
26. Lang B, Vincent A, Murray M, Newsom-Davis J. LambertEaton myasthenic syndrome: immunoglobulin G inhibition of Ca2+ flux in tumor cells correlates with disease severity. Ann Neurol 1989;25:265-271.
27. Takamori M, Hamada T, Komai K, Takahashi M, Yoshida A. Synaptotagmin can cause an immune-mediated model of Lambêrt-Eaton myasthenic syndrome in rats. Ann Neurol 1994;35:74-80.
28. Hajela RK, Atchison WD. The proteins synaptotagmin and syntaxin are not general targets of Lambert-Eaton myasthenic syndrome autoantibody. J Neurochem 1995;64:1245-1251.